Pharmacotherapy for post traumatic stress disorder (PTSD)

Area of Science:

• Psychiatry
• Pharmacology
• Clinical Psychology

Background:

• Post-traumatic stress disorder (PTSD) is a significant mental health condition with considerable disabling effects.
• Growing evidence suggests psychobiological dysfunctions in PTSD, increasing interest in pharmacotherapy.
• Medication offers a potential avenue for managing PTSD symptoms and associated conditions.

Purpose of the Study:

• To systematically evaluate the efficacy of pharmacotherapy for post-traumatic stress disorder (PTSD).
• To assess the impact of various medication classes and agents on PTSD symptom severity and treatment response.
• To identify the most effective medication strategies for managing PTSD and its comorbidities.

Main Methods:

• Conducted a comprehensive search of multiple databases including Cochrane, MEDLINE, and PsycINFO up to December 2004.
• Included all randomized controlled trials (RCTs) investigating pharmacotherapy for PTSD.
• Utilized independent assessment of RCTs, data collation, quality assessment, and random effects modeling for analysis.

Main Results:

• Analysis of 35 RCTs (4597 participants) showed significant symptom reduction with medication compared to placebo.
• Medications demonstrated superiority in reducing PTSD symptom clusters, comorbid depression, and disability.
• Selective serotonin reuptake inhibitors (SSRIs) showed the most convincing evidence of efficacy, with improved tolerability over placebo.

Conclusions:

• Pharmacotherapy is effective in treating PTSD, alleviating core symptoms, depression, and disability.
• SSRIs are supported as first-line agents for PTSD pharmacotherapy, with potential long-term benefits.
• Despite positive findings, gaps in evidence necessitate the development of more effective PTSD treatments.